Marwan Saoud, MD
Critical Care Medicine · Buffalo, NYNPI 1083025985
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.6%), education and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 60.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $4,654 and has fallen 76.1% since, to $1,113 in 2025. Among critical care medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $54.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$654
- AstraZeneca$505
- Boehringer Ingelheim$263
- Sanofi$161
- Actelion Pharmaceuticals US, Inc.$136
- plus $927 from 19 others
What the payments were for
- Travel & lodging$1,30119%
- Food & beverage$2,78042%
- Education$2,60739%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $4,042 |
| GSK | 32 | $654 |
| AstraZeneca | 21 | $505 |
| Boehringer Ingelheim | 6 | $263 |
| Sanofi | 6 | $161 |
| Actelion Pharmaceuticals US, Inc. | 5 | $136 |
| Pentax Of America, Inc. | 2 | $107 |
| Grifols USA, LLC | 5 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Viatris Specialty LLC | 4 | $86 |
| Amgen | 4 | $80 |
| Insmed, Inc. | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 3 | $57 |
| Mylan Specialty L.p. | 3 | $51 |
| Merck | 2 | $44 |
| Vifor Pharma, Inc. | 1 | $31 |
| Pfizer | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Johnson & Johnson | 1 | $25 |
| Electromed, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Verona Pharma, Inc. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Inogen, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,667
- TAGRISSO$125
- NUCALA$125
How this compares
$6,689 in reported general payments places this provider in the 90th percentile of 442 critical care medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 62 | $805,972 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 343 | $251,892 |
| NucalaMepolizumab | 36 | $144,470 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 144 | $90,822 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $16,428 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 77 | $13,708 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $13,684 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $11,134 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $11,071 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 335 | $10,869 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $10,417 |
| Spiriva RespimatTiotropium Bromide | 12 | $7,170 |
| Mycophenolate Mofetil | 37 | $6,956 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,528 |
| Tiotropium Bromide | 16 | $5,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $263 | $824,21394 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $654 | $435,958458 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $505 | $107,249195 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 critical care medicine providers in New York.
Other critical care medicine in Buffalo
- Kumar ShahBuffalo$5K
- Joshua RosenbergBrooklyn$881K
- Peter DicpinigaitisBronx$241K
- Roxana SulicaNew York$211K
- Boris ShkolnikAlbany$209K
- Paul StrachanMelville$169K
- Anna PodolanczukNew York$116K
- Joanne HessneyRochester$76K
- Jan BakkerNew York$49K
- Hugh CassiereManhasset$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.